Every pharma distributor, stockist and PCD franchise owner has seen it: a shelf of medicines that were ordered with confidence but now sell a few strips a month. Knowing how to manage slow-moving medicine stock in a pharma business is not only about clearing shelves. It protects working capital, warehouse space, medicine quality and your relationships with suppliers and customers.
Medicines become slow-moving for many reasons: inaccurate demand forecasts, bulk purchases made for a discount, seasonal swings, a doctor changing prescribing habits, or simply weak stock monitoring. Because medicines carry an expiry date, the problem has a clock attached. Stock that sits unsold does not just wait; it loses shelf life.
Four terms are often used as if they mean the same thing, but they do not:
- Slow-moving stock: sells, but much more slowly than the quantity you hold.
- Excess stock: quantity above what you can reasonably sell before expiry. It may sell well, just not well enough.
- Dead (non-moving) stock: no meaningful sales for a long period.
- Near-expiry stock: batches with limited shelf life left, whatever their sales speed.
These categories overlap. A slow-moving batch can become excess stock, then near-expiry stock, and finally expired stock. This guide shows how to spot the problem early and act before losses grow, without compromising patient safety or regulatory requirements.
What Is Slow-Moving Medicine Stock?
Slow-moving medicine stock is inventory whose sales rate is low compared with the quantity on hand. The word “compared” matters. Ten strips sold per month is slow if you hold 600 strips, but perfectly healthy if you hold 30.
To judge movement properly, look at four things together: sales history, how often you purchase the item, the demand pattern (steady, seasonal or occasional), and the remaining shelf life of each batch. Low sales alone do not make a product unprofitable or unnecessary. A specialist injectable or a chronic-care formulation may sell in small numbers but be important to a few loyal doctors and chemists. The question is whether your stock matches realistic demand.
Simple illustrative example
Hypothetical figures, for illustration only: a distributor holds 600 bottles of a syrup. Sales over the last six months averaged 40 bottles a month. At that rate, the stock equals 15 months of sales. If the shelf life left is only 12 months, some stock is likely to expire unsold, even though the product is “selling”.
Why Does Medicine Stock Become Slow-Moving?
Most slow-moving stock is created by decisions, not by bad luck. Common causes in Indian pharma distribution include:
- Over-purchasing for bulk discounts. A scheme looks attractive on the invoice, but the saving disappears if the extra quantity sits for months.
- Poor sales forecasting. Ordering by habit or gut feeling instead of recent sales data.
- Wrong local demand estimates. A product that sells well in one district may not suit another, depending on doctors, disease patterns and competing brands.
- Seasonal demand. Cough, cold, rehydration and skin products can swing sharply with weather. Stock bought for a peak may remain after it ends.
- Expanding the range too fast. Every new product adds an SKU (stock keeping unit) to track and a new chance of slow movement.
- Ordering without checking current stock. Repeat orders get placed because nobody looked at what was already in the godown.
- Weak coordination. Sales, purchase and warehouse teams work from different information.
- Changing prescribing patterns. A doctor shifts to another combination or brand and demand falls.
- Inadequate tracking. Without batch-wise reports, ageing stock stays invisible.
- Supplier minimum order quantities (MOQs). If the MOQ is bigger than your actual demand, you can end up with surplus on day one.
- A long tail of low-selling SKUs. In a large portfolio, many items individually sell slowly and together lock up significant cash.
How to Identify Slow-Moving Medicine Stock Early
The aim is to see the problem while there is still time to act. Useful checks include:
- Regular sales and stock movement reports.
- SKU-wise analysis of purchases, sales and closing stock.
- Batch-wise stock and expiry tracking.
- Stock ageing reports showing how long each batch has been held.
- Months (or days) of inventory on hand: closing stock divided by average sales.
- Comparing stock levels with average sales, item by item.
- Listing products with no sales over a period you define.
- Flagging items whose inventory is unusually high compared with demand.
There is no single review period that suits every product. The right interval depends on the product category, its sales cycle, seasonality and shelf life. A seasonal syrup with a short shelf life needs closer watching than a stable chronic-care tablet. Any thresholds you set, such as “no sale in 90 days”, are examples to adapt and not industry standards.
| Indicator | What It Tells You | Suggested Action |
|---|---|---|
| Slow sales | Product movement is below expectations | Review recent demand and stock quantity |
| High stock relative to sales | Inventory may exceed realistic demand | Recalculate purchasing requirements |
| No sales for an extended period | Product may be non-moving | Investigate the cause and decide next steps |
| Approaching expiry | Less time remains to sell or otherwise manage the stock | Review batch-level options immediately |
| Repeated overstocking | Purchasing may not match actual demand | Improve forecasting and reorder controls |
1. Implement FEFO-Based Stock Rotation
FEFO stands for First Expiry, First Out. Under FIFO (First In, First Out), the batch received first is dispatched first. Under FEFO, the batch that expires first is dispatched first, even if it arrived later. Because two batches of the same product can have very different expiry dates, FEFO is usually the safer basis for pharma stock rotation.
To make FEFO work in practice:
- Record batch number and expiry date accurately at goods receipt, and again at dispatch.
- Arrange the warehouse so that earlier-expiry batches are easy to see and reach.
- Use inventory software or a well-maintained stock register that shows batch-wise quantities.
- Check periodically that pickers are actually following FEFO.
- Keep expired, damaged, recalled or otherwise unsuitable products out of saleable stock. Mark and segregate them immediately.
Storage conditions also affect how long a batch stays usable, so rotation and storage go together. Rosette Pharma’s article on why storage conditions matter for pharmaceutical products explains temperature, humidity and light considerations for distributors and stockists.
FEFO limits expiry exposure, but it does not fix weak demand or excessive buying. It only decides which batch leaves first.
For reference, the WHO’s Good storage and distribution practices for medical products (TRS 1025, Annex 7) includes a section on stock control and rotation. In India, CDSCO has published a draft guidance on Good Distribution Practices for pharmaceutical products. The version we reviewed is marked as draft guidance for feedback, so treat it as a reference point and not as a binding rule. Check the current status with CDSCO or your State Drug Licensing Authority.
2. Review Your Purchasing and Reordering Strategy
Better purchasing is the most direct way to stop slow-moving stock from forming. Build these habits:
- Check current inventory, including pending orders, before placing any new order.
- Set a reorder point (the stock level that triggers an order) and minimum and maximum stock levels for each product.
- Consider average sales, supplier lead time, seasonal demand and a modest safety stock.
- Do not buy in bulk only because of a discount. Compare the discount with the cost of holding stock and the risk of expiry.
- Evaluate supplier MOQs against your real demand; negotiate where they are too high.
- Use different stocking rules for fast-moving and slow-moving products.
- Estimate the money tied up in excess inventory before approving a purchase.
Simple illustrative reorder example
Hypothetical assumptions: average sales are 40 strips a month, supplier lead time is half a month, and you keep a safety stock of 20 strips.
- Reorder point = (40 × 0.5) + 20 = 40 strips.
- Maximum level, if you decide to hold at most three months of sales = 40 × 3 = 120 strips.
- If you already hold 300 strips (about 7.5 months of sales), no new order should be placed.
Your own numbers will differ. The point is to replace “order again” with a rule based on data.
3. Use Sales Data and Demand Forecasting
Medicine demand forecasting does not need complex tools. Start with what you already have:
- Review recent monthly sales for each SKU.
- Identify seasonal patterns by comparing the same months across years.
- Track repeat orders from regular customers.
- Separate regular demand from one-time bulk orders so a single big order does not inflate your forecast.
- Watch for trend changes, such as three months of declining sales.
- Ask sales representatives and key chemists what they expect.
A well-organised spreadsheet is enough to begin with. Rosette Pharma’s guide on how pharma distributors can increase sales also touches on inventory planning and using data to anticipate demand.
Remember that past sales are a useful indicator, not a guarantee. A new competitor, a doctor’s change in prescription habits or a supply disruption can change the picture quickly.
4. Classify Inventory Using ABC and Movement Analysis
ABC analysis ranks items by their contribution to annual consumption value (quantity used multiplied by cost), not by how fast they sell. Class A items are the few products that account for most of the value, class B is a middle group, and class C is the large number of low-value items. The exact split varies by business.
Movement analysis is a separate view: fast-moving, slow-moving and non-moving. Combining the two gives better control:
- High-value and slow-moving: needs the closest attention, because each unit holds a lot of cash.
- High-value and fast-moving: protect availability and review often.
- Low-value and slow-moving: keep small quantities and review less often.
- Low-value and fast-moving: simple, routine reorders usually work.
Hypothetical example: a distributor finds that an expensive injectable (high value) sells only 6 vials a month. It is moved to a tight maximum of two months’ cover and reviewed monthly, while a low-cost fast-moving tablet is reordered on a simple fixed schedule. The aim is to avoid applying one purchasing rule to every product.
5. Manage Near-Expiry Stock Responsibly
Start by identifying batches approaching expiry early enough to have real options. Run batch-wise expiry reports and hold a regular near-expiry review. Then consider only legitimate steps:
- Contact the authorised supplier or manufacturer to ask about return or exchange options, where the contract and applicable rules allow it. Do not assume they must accept returns; policies and agreements vary. Asking about a manufacturer’s expiry and stock-return policy before you sign is a good habit, and Rosette Pharma’s guide to choosing a pharma manufacturing company lists it among the questions to ask.
- Where permitted, review transfers between authorised locations, with full traceability and suitable storage conditions.
- Check the contractual terms and the tax documentation needed for any return or transfer.
- Keep expired, recalled, damaged or doubtful products physically separate from saleable stock.
- Follow the applicable requirements for returns, disposal, documentation and record keeping.
The WHO also publishes points to consider for setting the remaining shelf life of medical products upon delivery (listed under its distribution guidelines), which is a useful reference when you define your own minimum shelf-life rules.
Important: never sell or distribute expired medicines, hide expiry dates, alter labels, repack stock to misrepresent expiry, or supply products that may expire before they can reasonably be used. Near-expiry stock must never be pushed onto customers regardless of their needs. These practices harm patients and can lead to serious legal and reputational consequences.
6. Improve Coordination Between Sales, Purchase and Warehouse Teams
Inventory decisions made in isolation usually create overstock. Simple steps help:
- Share a stock report with sales representatives regularly.
- Review customer feedback and the reasons for lost orders.
- Ask sales teams to check existing availability before they promise a new purchase to a customer.
- Assign clear responsibility for stock reviews.
- Record the reason whenever overstocking happens.
- Hold a short weekly or monthly inventory meeting.
Practical example: a sales representative learns that two chemists want a particular tablet and tells the purchase team to reorder. Because the weekly stock report is shared, the purchase manager sees that 400 strips are already in stock under a different batch. The order is cancelled, and the representative directs the chemists to the existing stock. One short conversation avoids an unnecessary repeat order.
7. Use Inventory Software or a Structured Stock Register
A good system makes everything above easier. Whatever you use, it should capture:
- Product and SKU identification.
- Batch-wise quantities, with manufacturing and expiry dates where applicable.
- Purchase and sales history.
- Stock ageing.
- Low-stock and near-expiry alerts.
- Returns and damaged-stock records.
- Stock reconciliation and an audit trail of adjustments.
A small business can begin with a properly structured spreadsheet or register, provided it is updated every day and checked against physical stock. Larger operations may benefit from dedicated inventory or ERP software. Choose based on your volume, number of SKUs and team size, not on brand names.
8. Reduce Future Slow-Moving Stock Through Better Business Decisions
Prevention is cheaper than clearance. Consider these habits:
- Review how existing products perform before expanding the catalogue.
- Match inventory depth to local customer demand.
- Set purchase limits for products with uncertain movement.
- Negotiate realistic order quantities with suppliers.
- Periodically review discontinued or persistently non-moving products.
- Monitor the cash tied up in inventory.
- Track expiry-related losses month by month to see whether they are improving.
For a PCD pharma franchise business, territory demand matters a great deal. Your doctors’ prescribing habits, your chemists’ order patterns, the seasonal disease profile of your district and the products you choose to stock all influence how much inventory makes sense. A new franchise partner can begin with a focused range, watch actual movement and add products gradually. No business model or product list guarantees sales or profit, so plan inventory around your own territory’s data.
Example: A Practical Slow-Moving Stock Management Plan
All figures below are hypothetical and are for illustration only. They do not reflect Rosette Pharma’s business, records, customers or results.
A distributor reviews a 100 ml syrup. Purchase cost is assumed to be ₹60 per bottle.
- Identify the issue. The monthly stock report flags the syrup: 600 bottles on hand against average sales of 40 bottles a month over six months.
- Check batches and expiry. Batch A has 250 bottles with 7 months of shelf life left. Batch B has 350 bottles with 14 months left.
- Calculate stock against sales. 600 ÷ 40 = 15 months of stock. At 40 bottles a month, about 560 bottles would sell in 14 months, so roughly 40 bottles (about ₹2,400 at cost) are at risk even if demand holds. The cash locked in the stock is 600 × ₹60 = ₹36,000.
- Review upcoming purchase orders. A pending order for 500 more bottles is put on hold and a purchase-limit rule is set.
- Check lawful options. The team reads the supplier agreement and asks the authorised supplier whether any return, exchange or transfer is possible. The answer may be yes or no. Nothing is assumed, and any step is documented.
- Adjust future orders. A maximum level of three months of sales (120 bottles) and a reorder point are fixed. Dispatch follows FEFO, and the business sets a minimum remaining shelf life for dispatch so that no customer receives stock that cannot reasonably be used.
- Monitor results. Months of cover, batch expiry and write-offs for this product are reviewed monthly, and the reason for the original overstock is recorded.
Common Mistakes to Avoid When Managing Pharma Inventory
- Buying only to obtain bulk discounts.
- Ignoring batch-level expiry dates.
- Using FIFO without considering expiry priority.
- Ordering without checking current inventory.
- Treating all products as equally important.
- Waiting until stock is close to expiry before reviewing it.
- Assuming suppliers will accept returns.
- Distributing unsuitable or expired medicines.
- Failing to document stock adjustments.
- Basing forecasts on a single unusual sales period.
Frequently Asked Questions
1. What is slow-moving medicine stock?
It is medicine inventory that sells much more slowly than the quantity you hold. It is judged using sales history, purchase frequency, demand pattern and remaining shelf life, and is different from dead stock (no meaningful sales) and near-expiry stock.
2. How can a pharma distributor identify slow-moving stock?
Use SKU-wise sales and stock reports, batch-wise expiry tracking, stock ageing and months of inventory on hand. Compare stock with average sales and flag items with unusually high cover or no recent sales.
3. What is the difference between FEFO and FIFO in pharma inventory?
FIFO dispatches the batch received first. FEFO dispatches the batch that expires first. FEFO is generally more suitable for medicines because batches of the same product can have different expiry dates.
4. How can pharmaceutical businesses reduce expiry-related losses?
Buy in line with realistic demand, track batches and expiry dates, follow FEFO, review near-expiry stock early, and discuss lawful return or exchange options with authorised suppliers. Keep records of expiry-related losses so that you can see the trend.
5. How often should medicine inventory be reviewed?
It depends on the product, sales cycle, seasonality and shelf life. As an example, many businesses check fast-moving items weekly, run a monthly stock and expiry review, and review the wider portfolio quarterly. Adapt this to your own business.
6. Can slow-moving medicines be returned to suppliers?
Sometimes, but not automatically. Return and exchange terms depend on your agreement with the supplier or manufacturer and on applicable requirements. Ask about the policy before purchasing, and confirm the documentation needed.
7. How can a small pharma business manage stock without expensive software?
Use a structured spreadsheet or register with product, batch, expiry, purchase, sales and closing stock. Update it daily, reconcile it with physical stock regularly, and add a monthly near-expiry check.
8. How can PCD pharma franchise businesses prevent overstocking?
Start with a focused product range, order based on actual territory demand, set maximum stock levels, review monthly sales by product, and expand the range only after seeing how current products move.
9. What should a business do with expired medicines?
Segregate and clearly mark them as expired, record them, and keep them out of saleable stock. Then follow the applicable return or disposal procedure, including documentation. Confirm the requirements with your licensing authority and the manufacturer’s instructions. Never sell expired medicines.
10. How does demand forecasting help pharma inventory management?
It helps you estimate how much you are likely to sell, so you can order the right quantity at the right time. Better forecasts reduce excess stock, expiry risk and stock-outs, though they remain estimates and need regular review.
Conclusion
Managing slow-moving medicine stock in a pharma business comes down to a few disciplined habits: spot problem stock early, track every batch and its expiry, follow FEFO, buy according to data, forecast demand with the information you have, and keep sales, purchase and warehouse teams aligned. None of this requires expensive systems to start.
The goal is not to hold as little stock as possible. It is to keep the right availability for your customers while reducing unnecessary pressure on working capital, expiry risk and avoidable losses, and while keeping medicine quality and patient safety first.
Rosette Pharma, based in Karnal, Haryana, works with businesses in the pharmaceutical sector through PCD franchise and third-party manufacturing models. If you are exploring products, a franchise territory or manufacturing support and would like to discuss your requirements, you are welcome to get in touch with the Rosette Pharma team.
This article is for general educational purposes. It is not legal, tax or regulatory advice. Please confirm applicable requirements with the relevant authorities and your advisers.
